Teva Pharmaceutical Industries, a Jerusalem-based drugmaker, recently earned Food and Drug Administration approval for its abacavir and lamivudine tablets to treat adults with HIV-1 infection.
Abacavir and lamivudine tablets are a generic version of GlaxoSmithKline's Epzicom tablets. Epzicom tablets reported annual sales of about $449 million in the U.S. as of July 2016, according to IMS data.
At present, Teva has more than 300 products pending approval from the FDA.
More articles on supply chain:
US businesses' most pressing supply chain concerns: 4 things to know
8 latest FDA approvals
Why EpiPens are so much cheaper in Europe